Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential in...

Read More